PERK antibody | knockout validation | Cell Signaling 5683

This is a knockout-validated antibody summary, based on the publication "The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma", as cited below [1] and "Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy" for western blot knockout validation (figure s1a) [2]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

PERK antibody | knockout validation | Cell Signaling 5683 figure 1
Figure 1. Western blot analysis of cytoplasmic extracts from wild type (WT) 786-O cells and their knockout counterparts treated with 10 μM of sunitinib (Sun). From [1].
Antibody information

Rabbit monoclonal IgG

Company: Cell Signaling

Antibody: PERK

Catalog number: 5683

Summary: Rabbit monoclonal IgG against a synthetic peptide corresponding to residues surrounding Leu156 of human PERK protein. Reacts with human by western blot, immunoprecipitation and immunohistochemistry (paraffin).

Validation Method

Western blot

Sample

Wild type and PERK-KO 786-O cells.

Blocking agent

5% nonfat dry milk overnight.

Primary incubation

For 2 h.

Secondary incubation

Horseradish peroxidase-conjugated secondary antibody for 30 min.

Detection

Enhanced chemiluminescence (ECL Western Blotting Kit, Amersham).

References
  1. Makhov P, Naito S, Haifler M, Kutikov A, Boumber Y, Uzzo R, et al. The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma. Cell Death Dis. 2018;9:374 pubmed publisher
  2. Mahameed M, Boukeileh S, Obiedat A, Darawshi O, Dipta P, Rimon A, et al. Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy. Nat Commun. 2020;11:1304 pubmed publisher